Male Breast Cancer Patients Research Articles

Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.

Simple SummaryMale breast cancer (mBC) is a rare disease associated with a high prevalence of pathogenic germline variants (PVs) in the BRCA2 gene. However, data regarding other breast cancer (BC) predisposition genes are limited or conflicting. We investigated the prevalence of PVs in BRCA1/2 and 23 other cancer predisposition genes using an overall study sample of 614 patients with mBC. A high proportion of patients with mBC carried pathogenic germline variants in BRCA2 (23.0%, 142/614) and BRCA1 (4.6%, 28/614). A BRCA1/2 PV prevalence of 11.0% was identified in patients with mBC without a family history of breast and/or ovarian cancer. Patients with BRCA1/2 PVs did not show an earlier disease onset than those without. Case-control analyses revealed significant associations of protein-truncating variants in BRCA1, BRCA2, CHEK2, PALB2, and ATM with mBC. Our findings support the benefit of multi-gene panel testing in patients with mBC.Male breast cancer (mBC) is associated with a high prevalence of pathogenic variants (PVs) in the BRCA2 gene; however, data regarding other BC predisposition genes are limited. In this retrospective multicenter study, we investigated the prevalence of PVs in BRCA1/2 and 23 non-BRCA1/2 genes using a sample of 614 patients with mBC, recruited through the centers of the German Consortium for Hereditary Breast and Ovarian Cancer. A high proportion of patients with mBC carried PVs in BRCA2 (23.0%, 142/614) and BRCA1 (4.6%, 28/614). The prevalence of BRCA1/2 PVs was 11.0% in patients with mBC without a family history of breast and/or ovarian cancer. Patients with BRCA1/2 PVs did not show an earlier disease onset than those without. The predominant clinical presentation of tumor phenotypes was estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and HER2-negative (77.7%); further, 10.2% of the tumors were triple-positive, and 1.2% were triple-negative. No association was found between ER/PR/HER2 status and BRCA1/2 PV occurrence. Comparing the prevalence of protein-truncating variants (PTVs) between patients with mBC and control data (ExAC, n = 27,173) revealed significant associations of PTVs in both BRCA1 and BRCA2 with mBC (BRCA1: OR = 17.04, 95% CI = 10.54–26.82, p < 10−5; BRCA2: OR = 77.71, 95% CI = 58.71–102.33, p < 10−5). A case-control investigation of 23 non-BRCA1/2 genes in 340 BRCA1/2-negative patients and ExAC controls revealed significant associations of PTVs in CHEK2, PALB2, and ATM with mBC (CHEK2: OR = 3.78, 95% CI = 1.59–7.71, p = 0.002; PALB2: OR = 14.77, 95% CI = 5.02–36.02, p < 10−5; ATM: OR = 3.36, 95% CI = 0.89–8.96, p = 0.04). Overall, our findings support the benefit of multi-gene panel testing in patients with mBC irrespective of their family history, age at disease onset, and tumor phenotype.

Response to "Re: 'Occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications-A qualitative study'".

Response to "Re: 'Occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications-A qualitative study'".

The role of postoperative radiation therapy in stage I–III male breast cancer: A population-based study from the surveillance, epidemiology, and End Results database

BackgroundThis study aimed to investigate the role of postoperative radiation therapy in a large population-based cohort of patients with stage I–III male breast cancer (MaBC). MethodsPatients with stage I–III breast cancer treated with surgery were selected from the Surveillance, Epidemiology, and End Results cancer database from 2010 to 2015. Multivariate logistic regression identified the predictors of radiation therapy administration. Multivariate Cox regression model was used to evaluate the predictors of survival. ResultsWe identified 1321 patients. Age, stage, positive regional nodes, surgical procedure, and HER2 status were strong predictors of radiation therapy administration. There was no difference between patients who received radiation therapy and those who did not (P = 0.46); however, after propensity score matching, it was associated with improved OS (P = 0.04). In the multivariate analysis of the unmatched cohort, the factors associated with better OS were administration of radiation therapy and chemotherapy. In the subset analysis of the unmatched cohort, postoperative radiation therapy was associated with improved OS in men undergoing breast-conserving surgery (BCS), with four or more node-positive or larger primary tumours (T3/T4). Furthermore, we found no benefit of radiation therapy, regardless of the type of axillary surgery in mastectomy (MS). In older MaBC patients with T1-2N1 who underwent MS, radiation therapy showed no significant effects, regardless of chemotherapy. ConclusionPostoperative radiation therapy could improve the survival of MaBC patients undergoing BCS, with four or more node-positive or larger primary tumours. Moreover, it should be carefully considered in patients undergoing MS and older T1-2N1 patients.

Impacts of subtypes on clinical feature and outcome of male breast cancer.

e12528 Background: The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry (IHC), their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea. Methods: We retrospectively analyzed clinical data of 248 MBC patients 18 institutions across the country from January 1995 to July 2016. Results: The median age of MBC patients was 63 years (range: 25–102 years). Among the 148 patients that underwent intrinsic subtype classification, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, HER2, and triple-negative breast cancer (TNBC), respectively. TNBC patients showed inferior survival compared with those with other subtypes. Of the 221 patients with operable breast cancer, 108 (48.6%) received adjuvant chemotherapy and 52 (23.5%) received adjuvant radiation therapy. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR] = 0.19, 95% confidence interval [CI] 0.005–0.65, P = 0.008) and in all patients (HR = 0.16, 95% CI 0.05–0.54, P = 0.003). Conclusions: Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients have tended to receive les treatment. MBC patients should be treated with standard guideline as FBC patients receive.

Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment.

Male breast cancer (MaBC) is a rare clinical entity, which makes up approximately 1% of all breast cancers. However, the incidence of MaBC has been steadily increasing over the past few decades. The risk factors for MaBC include age, black race, family history of breast cancer, genetic mutations, liver cirrhosis, and testicular abnormalities. The majority of patients with MaBC present with painless lumps, and about half of the patients have at least one lymph node involved at the time of diagnosis. The treatment of MaBC models that of female breast cancer (FeBC), but this is mainly due to lack of prospective studies for MaBC patients. The treatment modality includes surgery, adjuvant radiation, endocrine therapy, and chemotherapy. However, there are some distinct features of MaBC, both clinically and molecularly, that may warrant a different clinical approach. Ongoing multinational effort is required, to conduct clinical trials for MaBC, or the inclusion of MaBC patients in FeBC trials, to help clinicians improve care for MaBC patients.

PO-1178 Outcome of male breast cancer patients at an academic university hospital in India

PO-1178 Outcome of male breast cancer patients at an academic university hospital in India

Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis

IntroductionThe 21-gene assay provides prognostication for estrogen receptor positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) early female breast cancer patients. This signature has not been validated in male breast cancer (MBC). MethodsA systematic review and meta-analysis was performed in accordance to the PRISMA guidelines. Retrospective cohort studies comparing 21-gene assay scores in female and MBC were included. Dichotomous variables were pooled as odds ratios (OR) and associated 95% confidence intervals (CI) using the Mantel–Haenszel method. ResultsSix studies including 176,338 patients were included (mean age of 63.4 years, range: 33–88). Of these, 1.0% had MBC (1826/176,338) and 99.0% were female patients (174,512/176,338). MBC patients were more likely to have increased tumour stage, nodal involvement, and grade 3 disease (all P < 0.001) In MBC patients, the mean score was 18.8 (range: 11–26) vs. 13.4 (range 0–33) in female patients (P < 0.001). In MBC patients, 22.4% had scores >30 (408/1822) versus 18.3% in female patients (31,852/174,500). In female patients, 52.0% had scores <18 (90,787/174,500) versus 47.8% in MBC (471/1822). Overall, patients with female patients were as likely to have scores <18 (OR: 1.04, 95% CI: 0.94–1.16), scores 18–30 (OR: 1.12, 95% CI: 1.00–1.26) and scores >30 (OR: 0.69, 95% CI: 0.45–1.07) as MBC patients. ConclusionThere are similar anticipated scores for female and MBC undergoing 21-gene expression assay testing for early stage, ER+/HER2-breast cancer. In the absence of stage matching, cautious interpretation of these results is required. Validation of the 21-gene assay in MBC is still required.

Male breast cancer: a Singapore perspective.

Male breast cancer (MBC) is rare, representing <1% of all breast cancers. Treatment recommendations have been extrapolated from trial data of female breast cancer patients. This study aims to report our institutional experience of MBC across a 20 year period, analyse the survival outcome and prognosis of this group against female breast cancer patients treated at the same centre. Clinical, histopathological, treatment and survival data of male and female breast cancer patients treated between Jan 1999 and July 2019 at Singapore General Hospital and National Cancer Centre Singapore were identified and analysed. Fifty-seven male patients were identified. The median age at diagnosis was 63 years. Majority had invasive ductal carcinoma (86%) and presented at an early disease stage: 70.2% presented as Tis/T1/T2 and 49.1% had no axillary nodal involvement. 84.2% had a simple mastectomy with either a sentinel lymph node biopsy or axillary clearance. The median follow up was 5.69 years for males and 5.83 years for females. The median survival was 11.86 years for males and 16.3 years for females. At 5 years, overall survival (OS) was 69.9% (52.3-82.1%) and disease free survival (DFS) was 62.9% (44.9-76.5%) for males compared with OS 83.8% (83.21-84.39%) and DFS 74.5% (73.91-75.09%) for females. MBC remains understudied. Our institutional data indicates that good long term survival in South-East Asian patients can be achieved with treatment protocols that are similar to female breast cancer. More prospective studies are required.

Survival Analysis in Male Breast Cancer With Bone Metastasis Based on the SEER Database.

PurposeBreast cancer (BC) has been extensively and deeply studied as the number one malignant tumor in women, but its status in male patients, especially in male metastatic patients, is rarely reported. Thus, this study aimed to explore the prognosis and risk factors of male BC with bone metastasis.Patients and MethodsWe searched the Surveillance, Epidemiology, and End Results (SEER) database to identify all patients diagnosed with male BC with bone metastasis from 2010 to 2016. Risk factors of overall survival (OS) and cancer-specific survival (CSS) were analyzed by univariable and multivariable Cox analyses. We also drew Kaplan–Meier plots to show the correlation between independent risk factors and survival.ResultsA total of 207 male BC patients with bone metastasis were included for analysis. Approximately one-third of patients also had lung metastasis. Luminal A subtype comprised 58.5% of the overall patient population. These patients had a poor prognosis, with 3-year OS and CSS rates, 36.7% and 39.5%, respectively. Further analysis revealed that age ≤60 years old, luminal A or B, and surgery were independent predictors of prolonged OS and CSS. On Cox multivariable analysis, brain metastasis was associated with OS and not CSS.ConclusionWe identified four independent factors associated with prognosis in male BC patients with bone metastasis, namely age, tumor subtype, surgery, and brain metastasis. Knowing these risk factors will help clinicians make more appropriate treatment plans.

Re: ‘Occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications—A qualitative study’

Re: ‘Occupational rehabilitation of male breast cancer patients: Return patterns, motives, experiences, and implications—A qualitative study’

Effect of Breast Conservation Therapy vs Mastectomy on Overall Survival and Breast Cancer-Specific Survival Among Men With Stage I-II Breast Cancer: Analysis of SEER, 2000-2018

BackgroundMale breast cancer is a rare malignant tumor, and outcomes of breast conservation therapy (BCT) are currently lacking. MethodThe retrospective, population-based cohort study included 1369 stage I-II (T1–2 N0–1 M0) male breast cancer patients from the SEER database (2000-2018). The patients were grouped in two groups: BCT group and mastectomy group, according to surgical and radiation therapy. Kaplan-Meier method and univariable Cox proportional hazard analysis were used to compare overall survival (OS) and breast cancer-specific survival (BCSS) between two treatment groups. Propensity score matching (PSM) was performed to balance the confounding factors. ResultsOf the 1369 men, 97 (7%) patients received BCT, 1272 (93%) received mastectomy alone. The 5- and 10-year OS rates were 92.3% and 80.7% for BCT group compared with 80.4% and 61.4% for mastectomy group. The 5- and 10-year BCSS rates were 96.5% and 93.9% for patients undergoing BCT, as compared with 93.1% and 84.4% for patients undergoing mastectomy. Compared with mastectomy group, BCT group showed improved OS (hazard ratio [HR], 0.294; 95% CI 0.138-0.623, P = .002) and BCSS (hazard ratio [HR], 0.182; 95% CI 0.040-0.820, P = .027). Of the 791 patients with T1 stage, BCT showed insignificant association with OS (hazard ratio [HR], 0.555; 95% CI 0.207-1.488, P = .242) and BCSS (hazard ratio [HR], 1.217; 95% CI 0.171-8.675, P = .844). ConclusionThe results of this cohort study suggest that BCT is at least equivalent to mastectomy in male breast cancer patients. The underlying mechanism of this association needs further research.

Male Breast Cancer: The Three Decades' Experience of a Tertiary Care Hospital in a Lower-Middle Income Country.

IntroductionMale breast cancer is uncommon and managed on the guidelines of female breast cancer due to tumor rarity. We sought to identify the incidence, clinicopathological features, and survival of all male breast cancer patients managed in our hospital.MethodsA retrospective cross-sectional study was conducted at Aga Khan University Hospital (AKUH), Karachi, Pakistan, from January 1986 to December 2018. Demographic data, treatment records, and follow-up data of all male breast cancer patients who were treated at AKUH was reviewed.ResultsThirty-eight out of 42 patients who presented over a period of 32 years were included. The mean age was 63 years. The most common tumor type and subtype were invasive ductal carcinoma (89.5%) and luminal A (73.7%), respectively. The majority (36.8%) of the patients presented at stage III. Among 30 (78.9%) patients who underwent surgery, mastectomy was performed in 30 (78.9%), upfront axillary clearance in 24 (63.2%), axillary sampling in five (15.1%) cases, and sentinel lymph node biopsy in one (2.6%) case. Neoadjuvant chemotherapy was given to 10 (26.3%) patients, and adjuvant chemotherapy to eight (21.1%) patients. Adjuvant hormonal treatment was administered to 22 (57.9%) patients, and 13 (34%) patients received adjuvant radiation to the chest wall. The five-year overall survival was 38.2% and the median survival was 36 months. The five-year disease-free survival (DFS) was found to be 33.7%.ConclusionBreast cancer in males presents at an advanced stage with poor survival. Multicenter studies are required to accurately identify incidence, prognostic factors, and outcomes in order to have a better understanding of its management.

Abstract P2-09-13: Is there a male breast cancer cluster region in the BRCA2 gene?

Abstract Background: The location of the variant in the BRCA2 gene may have a role on the differential risk of hereditary breast-ovarian cancer (HBOC) families. Three Breast Cancer Cluster Regions (BCCR) have been previously identified in BRCA2: BCCR1- c.1-c.596; BCCR1’- c.772-c.1806; BCCR2- c.7394-c.8904. BCCR1 includes the Portuguese founder pathogenic variant (c.156_157insAlu), which explains up to 1/3 of hereditary breast cancer. As previously described one of the associated phenotypes of c.156_157insAlu is male breast cancer (MBC). We analyzed all MBC BRCA2 families registered in our program searching for a possible association between variant location in the BRCA2 gene and MBC. Methodology: This is a Portuguese, single-center, cross-sectional study, including all families identified with a pathogenic variant in the BRCA2 gene between December 1999 and December 2019. BRCA2 families with MBC cases were selected for further analysis including gene mapping of identified variants. The study was approved by our center’s IRB/IEC. Results: Of a total of 452 confirmed BRCA1/2 families, 285 were diagnosed with a BRCA2 pathogenic variant. Review of these 285 genograms identified 57 families with MBC in their phenotype, including 62 men diagnosed with 69 breast cancer cases (7 bilateral). Twenty-nine (47%) MBC patients were confirmed to be carriers of a BRCA2 pathogenic variant (26 tested, 3 obligate carriers); the others were considered to be probable BRCA2 carriers based on family analysis. Besides MBC other BRCA2-associated cancers were identified in these families: female breast cancer (FBC, 82%), prostate cancer (35%), gastric cancer (18%), pancreatic cancer (16%) and ovarian cancer (12%). In 6 (2%) BRCA2 families, breast cancer was exclusively diagnosed in men.Eighteen (32%) MBC patients were diagnosed with other cancers: 9 prostate, 5 colorectal, 3 gastric, 2 kidney, 1 bladder, 1 pancreatic and 1 central nervous system.The most commonly identified variant was the c.156_157insAlu (24, 38.7%), followed by c.9097dupA (6.5%), c.793+1G&amp;gt;A (4.8%) and c.2808_2811delACAA (4.8%).Thirty-six (63%) of the identified variants were located on the previously described BCCR (46% in BCCR1, 11% in BCCR1’ and 7% in BCCR2). The remaining variants were located in other areas of the BRCA2 gene: 12% closer to BRCA2 3’ terminal (exons 23-25); 1.8% in exon 8; and the remaining scattered through exon 11 (in 14% of cases in regions previously described as associated to ovarian cancer). The proportion of BCCR variants was significantly lower on confirmed carriers compared to probable carriers (48.3% vs 78.6%, chi-square p=0.018), due to a higher proportion of variants located on exons 23-25 (17.2% vs 7.1%) and on exon 11 (31% vs 14.2%). Approximately half of the bilateral MBC cases (57% of the total sample, 50% of the confirmed carriers) were associated with BCCR variants. Conclusion: Our data suggest that BCCR1 may be a male breast cancer cluster region (MBCCR). The clustering of confirmed MBC distal to BCCR2, closer to the BRCA2 3’ terminal, raises the possibility of a specific MBCCR, and warrants further research. Citation Format: Pedro Simões, Teresa Duarte, Joana Parreira, Ana Luís, Sandra Bento, Sofia Fragoso, Sidónia Santos, Fátima Vaz, Saudade André. Is there a male breast cancer cluster region in the BRCA2 gene? [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-09-13.

Abstract P3-12-31: A 10 year retrospective study of male breast cancer patients within central Scotland

Abstract Background. This study is a retrospective review of all of the male breast cancer patients treated within NHS Tayside, Scotland, over a 10 year period. The trust’s catchment area covers a population of 550,000 people. It evaluates several different important factors including epidemiology, patient presentation, pathology results, and treatment interventions. It also explores how choice of hormonal therapy influences patients’ overall outcomes. Materials And Methods. 33 patients in total were identified from the NHS breast cancer database. These results were then statistically analysed in order to determine overall trends within the data. Results. Patients’ ages ranged from 48 to 87 years old, with a mean age at 71 years. 94% of these patients had a palpable lump at presentation, with 42% having at least one palpable axillary node. 18% of patients experienced nipple discharge and 33% experienced some form of nipple distortion, confirming the fact that involvement of the nipple-areolar complex in males occurs early on and in a significant number of cases. 42% of patients experienced associated breast pain, a significantly higher rate than female breast cancer patients. The most common tumour grade was stage T2, highlighting the fact that males tend to be diagnosed on average 6-9 months later than females, who most commonly present at stage T1. The most common histological type was invasive ductal carcinoma (76% of cases). 66% of patients were ER+, PR+, HER2-. 61% of patients received surgical intervention. 33% underwent a sentinel lymph node biopsy (SLNB) and of these, 46% had node involvement. 27% of patients had axillary node clearance as part of their surgical intervention. 21% of patients had a synchronous malignancy at the time of diagnosis. This highlights that the majority of patients were elderly and as a result had other diseases of old age. The overall survival rate for our patient cohort was 55%, with a cancer specific survival rate of 88%. 33% of patients have completed 5 or more years of follow up. 30% are still within their 5 years of follow up, and 36% died within their 5 years of follow up, either as a result of their malignancy or for unrelated causes. Only 30% of patients were referred for genetic testing, with zero BRCA mutations identified, supporting the fact that contrary to popular belief, BRCA mutations occur in male breast cancer no more commonly than in female patients. The recurrence rate of the 11 patients receiving adjuvant Tamoxifen was 0, as was the recurrence rate of the 15 patients receiving adjuvant Letrozole. The similarities here can likely be attributed to the small sample size of this study, however it is now recognised that Tamoxifen should be the drug of choice. Letrozole has no effect on aromatase within the testes, which is responsible for 20% of oestrogen production. Conclusions. Male breast cancer is an important but often overlooked topic. Cases occur sporadically and are associated with old age, however there are a number of recognised risk factors including lifestyle and hormonal influences. A high proportion of patients will experience associated pain and early involvement of the nipple-areolar complex. A delay in diagnosis also means that many patients present at a higher stage of the disease, with more nodal involvement. Tamoxifen is the hormonal therapy of choice in these patients. Citation Format: Rachel EL Morris, Vasileios Pitsinis. A 10 year retrospective study of male breast cancer patients within central Scotland [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-12-31.

Abstract P1-23-01: Male breast cancer- a 20 year multi-center experience

Abstract Background-. Male breast cancer (MaBC) is a rare disease and accounts for approximately 1% of breast cancer. Treatment is largely extrapolated from female breast cancer (FeBC) due to lack of data in MaBC. However, there are distinct features of MaBC that warrant different treatment approach. We aim to better characterize the risk factors, clinicopathologic features, treatment and outcome of MaBC patients from 6 hospitals across Steward Healthcare Network. Methods-. 107 men with breast cancer were identified from the respective cancer registry at Steward and 64 patients were included with complete medical records. Their clinical, histopathological and treatment records were retrospectively reviewed. Results-. Of these 64 patients, median age at diagnosis was 68 years, 58 patients were white (90.6%), 13 patients had family history of breast or ovarian cancer (20.3%), 4 patients tested positive for BRCA2 (6.25%), 1 patient had liver cirrhosis, and no patient had Klinefelter syndrome or testicular dysfunction. 57 patients (89%) presented with a breast mass with 4 of these patients having nipple changes (6.25%). 59 patients (92.2%) had invasive ductal carcinoma, 42 patients (65.6%) had grade 2 tumors, 31 patients (48.4%) had tumor size between 2-5 cm, and 31 patients (48.4%) had lymph node involvement at time of diagnosis. 62 patients (96.8%) had M0 disease at time of diagnosis. 97% of patients had ER positive cancer, 87.5% of patients had PR positive cancer, and 7.8% of patients had HER2 positive cancer. Most patients underwent mastectomy (87.5%). Only 16% of patients with T1 tumors (5/31) underwent breast conserving surgery. 10 patients (15.6%) received neoadjuvant chemotherapy, 35 patients (54.6%) received adjuvant radiation therapy, 19 patients (30%) received adjuvant chemotherapy, and 98.4% of patients received adjuvant hormonal therapy. The median follow up was 71.5 months (range 6-250 months), 5-year survival rate was 86.9% (95% CI, 74.5% to 93.6%), 5-year relapse free survival rate was 89.9% (95% CI, 77.4% to 95.7%) and 10-year survival rate was 58.1% (95% CI, 41.0% to 71.8%). The presence of distant metastasis at the time of initial diagnosis was the only factor associated with shorter overall survival (hazard ratio 22.54, p &amp;lt;0.0001). Conclusion-. Majority of MaBC patients present with palpable breast mass and the tumors are almost exclusively hormone receptor positive. Majority of patients present without distant metastasis and received surgical therapy however only a small subset of patients received breast conserving surgery for T1 tumor. Almost all patients received adjuvant hormonal therapy. Overall survival and relapse free survival in our cohort is similar to historic reports in female breast cancer. Citation Format: Guoliang Zheng, Haoyang Wang, Fang-Yu Liu, Jose Pablo Leone. Male breast cancer- a 20 year multi-center experience [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-23-01.

A 10 Year Retrospective Study Of Male Breast Cancer Patients Within Central Scotland

Background: This study is a retrospective review of all of the male breast cancer (MBC) patients (pts) treated within NHS Tayside, Scotland, over a 10 year period. The trust’s catchment area covers a population of 550,000. It evaluates several different factors including epidemiology, patient presentation, pathology results, and treatment interventions. It also explores how choice of hormonal therapy influences overall outcomes.

Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer

Male breast cancer (MBC) is rare. Due to limited information, MBC has always been understudied. We conducted a retrospective population-based cohort study using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. The clinical and biological features of female breast cancer (FBC) patients were compared with MBC patients. Cox regression models and competing risks analyses were used to identify risk factors associated with cancer-related survival in MBC and FBC groups. Results showed that MBC patients suffered from higher TNM stages, tumor grades, and a higher percentage of hormone receptor-positive tumors, compared with FBC patients (all p < 0.05). In addition, the breast tumor locations varied a lot between males and females (p < 0.05). FBC patients were associated with superior overall survival than MBC patients. Results from multivariate cox regression and competing risks analyses showed age, race, T, N, M-stages, tumor grades, estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) overexpression were independent prognosis factors in FBC patients (all p < 0.05). MBC patients had similar risk factors to FBC patients, but PR and HER-2 status did not independently influence survival (all p > 0.05). Tumor location was an independent prognostic factor for both gender groups.

Hemogram index parameters in the evaluation of male breast cancer and inflammatory response: a case-control study

Our aim was to investigate the hemogram index parameters and their clinical significance in the evaluation of the inflammatory response of patients with male breast cancer, who are rarely observed in the literature. In total, 22 (n=22) healthy male and 28 (n=28) male breast cancer patients without synchronous/metachronous tumors were included in this study. They were grouped as the healthy male control group (Group 1) and the male breast cancer patient group (Group 2). The male breast cancer was divided into two subgroups, namely, early stage [(stage: 0/I/II) (Group 2A)] and late stage [(stage: III/IV) (Group 2B)], and their hemogram index parameters were compared. A significant (p>0.05) increase was observed in neutrophil/lymphocyte ratio (NLR) and·platelet/lymphocyte ratio (PLR) values in the late stage (Group 2B: stage III/IV) compared to the early stage (Group 2A: stage 0/I/II) and healthy control (Group 1) groups. In male breast cancer patients, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio values were significantly higher as the stage of cancer increased. These readily available simple tests can be used to evaluate the host's inflammatory response in male breast cancer.

The Prevalence and Death Risk of Male Breast Cancer: A Study Based on the Surveillance, Epidemiology, and End Results Database.

This study was to investigate the prevalence and death risk of male breast cancer (MBC) patients. The prevalence trend was based on the Surveillance, Epidemiology, and End Results (SEER) database from 1975 to 2017. A competitive risk analysis was performed to analyze the death risk of MBC patients. Hazard ratio (HR) and 95% confidence intervals (CIs) were calculated. The results indicated that the prevalence of MBC after the standardization of the total population increased in 1975–2017 and its annual percentage change (APC) was 0.536% (95% CI = [0.362%, 0.713%]). The prevalence of MBC was rapidly increased in patients aged ≥70 years (APC = 0.780%; 95% CI = [0.491%, 1.076%]) and Grade Ⅱ tumors (APC = 1.462%; 95% CI = [1.260%, 1.686%]). The 1-, 3-, and 5-year cumulative mortality of MBC patients who died of MBC was 2.23% (95% CI = [1.61%, 2.85%]), 7.56% (95% CI = [6.33%, 8.78%]), and 13.10% (95% CI = [11.10%, 11.32%]), respectively. Competitive risk analysis demonstrated that Blacks (HR = 1.76; 95% CI = [1.12, 2.77]), Grade 3 (HR = 2.56; 95% CI = [1.03, 6.35]), AJCC (American Joint Committee on Cancer) Stage Ⅲ (HR = 3.04; 95% CI = [1.76, 5.26]), and AJCC Stage Ⅳ (HR = 7.27; 95% CI = [1.36, 38.83]) were associated with an increased MBC-specific death risk, whereas married status (HR = 0.40; 95% CI = [0.25, 0.64]), surgery (HR = 0.25; 95% CI = [0.12, 0.50]), Luminal A subtype (HR = 0.20; 95% CI = [0.07, 0.53]), and Luminal B subtype (HR = 0.29; 95% CI = [0.10, 0.87]) were related to a reduced MBC-specific death risk. In addition, similar results can be observed in patients with surgery recommended and done (p < .05). This study may provide evidence for the prevalence trend, cumulative mortality, and death risk of MBC patients.

A 10 Year Retrospective Study of Male Breast Cancer Patients Within Central Scotland

Background: This study is a retrospective analysis of all of the male breast cancer (MBC) patients treated within Tayside, Scotland, over 10 years. It evaluates numerous aspects of diagnosis and intervention.